Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Kellton Tech Solutions Limited posts double-digit Q3 FY26 growth as digital transformation drives revenue; margins improve
Kellton Tech Solutions Limited (NSE: KELLTONTEC, BSE: 519602) reported double-digit year-on-year growth in revenue and…
-
Inox Green Energy Services Limited approves Q3 FY26 results and reappoints whole-time director
Inox Green Energy Services Limited (NSE: INOXGREEN, BSE: 543667) said its board approved the unaudited…
-
Huhtamaki India Limited reports flat Q4 2025 sales as margins improve on favorable mix and efficiency gains
Huhtamaki India Limited (NSE: HUHTAMAKI, BSE: 509820) reported broadly flat revenue in the fourth quarter…